BMS Spends $14 Billion to Buy Karuna Therapeutics and Novel Action Antipsychotic

Bristol Myers Squibb’s (BMS) $14 billion acquisition of Karuna Therapeutics accelerates the company’s diversification into the neuroscience space with Karuna’s priority asset, KarXT (xanomeline-trospium), leading the way.
Source: Drug Industry Daily